Last reviewed · How we verify
Poractant alfa (Curosurf®)
Poractant alfa is a natural pulmonary surfactant that reduces surface tension in the lungs and restores normal respiratory function in neonates with respiratory distress syndrome.
Poractant alfa is a natural pulmonary surfactant that reduces surface tension in the lungs and restores normal respiratory function in neonates with respiratory distress syndrome. Used for Respiratory distress syndrome (RDS) in premature infants, Meconium aspiration syndrome (MAS) in neonates.
At a glance
| Generic name | Poractant alfa (Curosurf®) |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Pulmonary surfactant replacement therapy |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Neonatology |
| Phase | FDA-approved |
Mechanism of action
Poractant alfa is an extract of porcine lung surfactant containing phospholipids and surfactant-associated proteins that mimics endogenous pulmonary surfactant. It is administered intratracheally to replace deficient or dysfunctional surfactant in premature infants, thereby reducing alveolar surface tension, preventing alveolar collapse, and improving lung compliance and gas exchange.
Approved indications
- Respiratory distress syndrome (RDS) in premature infants
- Meconium aspiration syndrome (MAS) in neonates
Common side effects
- Transient oxygen desaturation
- Bradycardia
- Reflux of surfactant into endotracheal tube
- Pulmonary hemorrhage
Key clinical trials
- Duration of Surfactant Administration and Impact on Stabilisation of Vital Parameters in Very Preterm Neonates: 1 Minutes Versus 5 Minutes (PHASE4)
- Surfactant Therapy Via Supraglottic Airway to Preterm Neonates With RDS in Vietnam (NA)
- Prospective, Non-Blinded, Randomized Controlled Trial on Early Administration of Pulmonary Surfactant Guided by Lung Ultrasound Scores in Very Preterm Infants. (NA)
- A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration (PHASE3)
- Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS) (PHASE2)
- A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS) (PHASE2)
- Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia. (PHASE3)
- A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Poractant alfa (Curosurf®) CI brief — competitive landscape report
- Poractant alfa (Curosurf®) updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI